Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trial
The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...
